ISRG
Intuitive SurgicalNASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-05-08
As of May 8, 2026, ISRG has a composite score of 20.7 and a signal label of "mild favorable." The score reflects a medium confidence level of 73.9. Key drivers include macro factors such as labor, rates, growth, and inflation, with notable scenarios indicating unfavorable guidance cuts and labor reversals, alongside favorable trends in the healthcare sector and potential guidance raises. This analysis is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.04
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $2.48 → $2.50 (+0.9% / 30d). 15 raised, 6 cut, 25 covering analysts.
0 upgrades, 0 downgrades / 30d, 9 maintained. 68% of analysts rate Buy.
3 PT revisions / 30d. Avg target 24.7% above current price.
2 positive, 0 negative / 30d. See F4 management tile for the event list.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
4 material events in the last 24 months — top 4 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Increase da Vinci proceduresgrowthmixed65% progress
4/21: “CEO: 'Worldwide procedures (da Vinci and Ion combined) grew approximately 17% compared with the first quarter of 2025.'”
Why this status
Stated in 2 of last 2 quarters. Worldwide procedures grew approximately 17% in 2026-Q1, indicating progress in increasing da Vinci procedures. However, the priority was previously marked as 'behind', suggesting ongoing challenges despite recent growth.
- 2.Maintain gross profit margincostbehind14% progress
4/21: “The Company expects non-GAAP gross profit margin to be within a range of 67.5% and 68.5% of revenue in 2026.”
Why this status
Stated in 3 of last 3 quarters. The company has consistently guided for a non-GAAP gross profit margin of 67.5% to 68.5% for 2026. Despite this focus, the priority was previously marked as 'behind', indicating challenges in maintaining the margin within the desired range.
- 3.Control operating expense growthcostbehind14% progress
4/21: “The Company expects non-GAAP operating expense growth of 11% to 14% in 2026.”
Why this status
Stated in 3 of last 3 quarters. The company has guided for non-GAAP operating expense growth of 11% to 14% for 2026. Despite this focus, the priority was previously marked as 'behind', suggesting difficulties in controlling expenses within the targeted range.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 32%; 252d 29%.
Drawdown — Max 1y −24%. Bad day move −3%.
Beta to sector ETF (XLV) — 0.70 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 52/100, drawdown 52/100, beta 70/100, earnings vol —.
Calm + bullish setup — clean pre-earnings positioning pattern.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Increase da Vinci procedures
GrowthNew since 2026-05-04Focus on expanding the number of da Vinci procedures performed globally.
Behind →MixedStated in 2 of last 2 quarters. Worldwide procedures grew approximately 17% in 2026-Q1, indicating progress in increasing da Vinci procedures. However, the priority was previously marked as 'behind', suggesting ongoing challenges despite recent growth.
65%CEO/CFO:“CEO: 'Worldwide procedures (da Vinci and Ion combined) grew approximately 17% compared with the first quarter of 2025.'”Press releaseSource dated 2026-04-21Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Press release
“Worldwide procedures (da Vinci and Ion combined) grew approximately 17%.”
- 2025-Q4Multiple sources
“Worldwide da Vinci procedure growth of approximately 17% to 17.5% in 2025.”
- #2
Maintain gross profit margin
CostNew since 2026-05-04Aim to sustain gross profit margins within the guided range for 2026.
BehindStated in 3 of last 3 quarters. The company has consistently guided for a non-GAAP gross profit margin of 67.5% to 68.5% for 2026. Despite this focus, the priority was previously marked as 'behind', indicating challenges in maintaining the margin within the desired range.
14%CEO/CFO:“The Company expects non-GAAP gross profit margin to be within a range of 67.5% and 68.5% of revenue in 2026.”Multiple sourcesSource dated 2026-04-21Stated 3 of last 8 quartersFirst seen 2026-05-04Show history (3)
- 2026-Q1Multiple sources
“Non-GAAP gross profit margin to be within a range of 67.5% and 68.5% of revenue in 2026.”
- 2025-Q4Multiple sources
“Non-GAAP gross profit margin to be within a range of 67% and 68% of revenue in 2026.”
- 2025-Q3Multiple sources
“Non-GAAP gross profit margin to be within a range of 67% and 67.5% of revenue in 2025.”
- #3
Control operating expense growth
CostNew since 2026-05-04Manage operating expense growth to remain within the guided range for 2026.
BehindStated in 3 of last 3 quarters. The company has guided for non-GAAP operating expense growth of 11% to 14% for 2026. Despite this focus, the priority was previously marked as 'behind', suggesting difficulties in controlling expenses within the targeted range.
14%CEO/CFO:“The Company expects non-GAAP operating expense growth of 11% to 14% in 2026.”Multiple sourcesSource dated 2026-04-21Stated 3 of last 8 quartersFirst seen 2026-05-04Show history (3)
- 2026-Q1Multiple sources
“Non-GAAP operating expense growth of 11% to 14% in 2026.”
- 2025-Q4Multiple sources
“Non-GAAP operating expense growth of 11% to 15% in 2026.”
- 2025-Q3Multiple sources
“Non-GAAP operating expense growth of 10% to 14% in 2025.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks more expensive than peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
ISRG Intuitive Surgical | +21 | full | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-04-21)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-04-21)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-044d agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Approval of the Amendment and Restatement of the Amended and Restated 2010 Incentive Award Plan The Board of Directors (the “Board”) of Intuitive Surgical, Inc. (the “Company”) previously adopted, subject to stockholder approval, the amendment and restatement of the Company’s Amended and Restated 2010 Incentive Award Plan (the “Amended 2010 Plan”),…
executive changeneutralscore 51 - 2026-04-2117d agoItem 2.02
Results of Operations and Financial Condition. On April 21, 2026 , Intuitive Surgical, Inc. (“Intuitive”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the…
earnings preannouncementpositivescore 49 - 2026-05-044d agoItem 7.01
Regulation FD Disclosure. On April 30, 2026, the Board increased the authorized amount available under the Company’s common stock repurchase program (the “Repurchase Program”) to an aggregate of $5.0 billion, including amounts remaining under previous authorization. The timing and total amount of repurchases will depend upon market conditions and may be made from time to time in open market purchases, privately negotiated transactions, accelerated share repurchase programs, issuer self-tender…
capital allocationpositivescore 47 - 2025-12-184mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective January 1, 2026, Brian E. Miller, Ph.D., will transition from his role as Chief Digital Officer of Intuitive Surgical, Inc. (the “Company”) and begin serving as Head of Digital and AI Strategy of the Company. In this role, Dr. Miller will no longer be reporting directly to the Company’s Chief Executive Officer. SIGNATURES Pursuant to the…
executive changeneutralscore 2
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.